Executive Vice President, Commercial 10 · REGENERON PHARMACEUTICALS, INC. (REGN)

Marion McCourt

A named executive officer of REGENERON PHARMACEUTICALS in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$6,899,939

Salary $706,300Stock awards $2,159,974

FY2018: $10,224,655

5th of 6 named executive officers at Regeneron Pharmaceuticals by FY2022 total.

6 named officers on file for REGENERON PHARMACEUTICALS, FY2022

Marion McCourt’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • REGN’s disclosed peer group of 11 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how REGENERON PHARMACEUTICALS’s whole pay program stands against its peers

  • REGENERON PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on REGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Marion McCourt’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Marion McCourt compensation by year

REGENERON PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as REGENERON PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2022
Salary$401,923$706,300
Bonus$0$0
Stock awards$4,671,325$2,159,974
Option awards$4,769,876$3,239,703
Non-equity incentive$372,281$780,462
Pension and deferred compensation$0$0
All other$9,250$13,500
Total$10,224,655$6,899,939

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENERON PHARMACEUTICALS, INC. DEF 14A filed April 21, 2023, accession 0001308179-23-000728, and prior-year filings. Open the filing on EDGAR.

How this page was built: the REGENERON PHARMACEUTICALS, INC. filed document, accession 0001308179-23-000728. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2023.

$10.2M
$6.9M
FY18
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$7,214,900—
RSU3,338$2,408,334—
RSU2,973$2,144,990—
RSU2,500$1,803,725—
RSU2,000$1,442,980—
RSU731$527,409—
RSU537$387,440—
Option10,689—$644.54
Option10,971—$726.53
Option12,500—$492.00
Option3,412—$372.46

Per the Outstanding Equity Awards at Fiscal Year-End table in REGENERON PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

20 Form 4 lines since the FY2022 proxy (filed April 21, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-16Sale10b5-149$960.3110,557
2026-11-16Sale10b5-159$954.4610,768
2026-11-16Sale10b5-163$965.6210,331
2026-11-16Sale10b5-159$961.3610,498
2026-11-16Sale10b5-142$963.7010,415
2026-11-16Sale10b5-144$952.7910,827
2026-11-16Sale10b5-141$962.4410,457
2026-11-16Sale10b5-130$955.5110,738

The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

REGENERON PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Andrew MurphyExecutive Vice President, Research$9,122,529
Daniel Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply$8,853,537
Robert LandryFormer Executive Vice President, Finance and Chief Financial Officer$8,838,493
Leonard SchleiferPresident and Chief Executive Officer$7,004,069
Marion McCourt · this pageExecutive Vice President, Commercial 10$6,899,939
George YancopoulosPresident and Chief Scientific Officer$6,593,696

The full REGENERON PHARMACEUTICALS compensation record

free company brief

This page is one person within REGENERON PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the REGENERON PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENERON PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Marion McCourt's compensation dossier · One-time report. No refunds.